Previous studies had proved bevacizumab blocks the binding of VEGF to VEGFR and reduces the level of nitric oxide that contributes to vasodilatation and causes adverse effects, such as proteinuria and hypertension [30]. This evidence concerns the gene KDR and hypertensive disorder.